Cosmo Bio Co., Ltd. (JP:3386)
:3386
Want to see JP:3386 full AI Analyst Report?
Top Page
Cosmo Bio Co., Ltd.
(3386)
Select Model
Select Model
Rating:70Outperform
Price Target:
¥1,438.00
▲(20.84% Upside)
Action:Upgraded
Date:02/18/26
Overall score is driven mainly by strong financial resilience from an exceptionally low-debt balance sheet and improved 2025 cash generation. Offsetting this, profitability has weakened significantly versus prior years, while technical signals are mixed and valuation is only moderate (supported by yield but not clearly cheap on P/E).
Positive Factors
Very low leverage / strong balance sheet
An extremely low debt load relative to equity gives enduring financial flexibility. It reduces bankruptcy risk, supports spending on R&D or inventory through cycles, and enables opportunistic M&A or capital returns without straining liquidity, strengthening long-term resilience.
Negative Factors
Material margin compression
Substantially lower margins and earnings indicate structural pressure on profitability, whether from pricing, cost inflation, or product mix shifts. If persistent, this erodes return on invested capital, limits reinvestment capacity, and weakens long-term shareholder value creation.
Read all positive and negative factors
Positive Factors
Negative Factors
Very low leverage / strong balance sheet
An extremely low debt load relative to equity gives enduring financial flexibility. It reduces bankruptcy risk, supports spending on R&D or inventory through cycles, and enables opportunistic M&A or capital returns without straining liquidity, strengthening long-term resilience.
Read all positive factors
Cosmo Bio Co., Ltd. (3386) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥7.18B
Dividend Yield4.57%
Average Volume (3M)81.79K
Price to Earnings (P/E)8.0
Beta (1Y)0.31
Revenue Growth8.02%
EPS Growth43.89%
CountryJP
Employees174
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)44.38
Shares Outstanding6,048,000
10 Day Avg. Volume21,560
30 Day Avg. Volume81,793
Financial Highlights & Ratios
PEG Ratio0.70
Price to Book (P/B)0.79
Price to Sales (P/S)0.69
P/FCF Ratio20.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Cosmo Bio Co., Ltd. Business Overview & Revenue Model
Company Description
Cosmo Bio Company,Limited engages in the import, export, manufacture, marketing, and sale of life science research biotools. Its life science research tools include reagents, kits, instruments, software, and diagnostics products. The company offer...
How the Company Makes Money
Cosmo Bio Co., Ltd. generates revenue primarily through the sale of life science research products and laboratory supplies. Key revenue streams include the distribution of high-quality reagents, antibodies, and diagnostic kits to various sectors s...
Cosmo Bio Co., Ltd. Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
92
Very Positive
Cash Flow
68
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 10.31B | 10.77B | 10.04B | 9.34B | 9.55B | 9.23B |
| Gross Profit | 3.48B | 3.70B | 3.33B | 3.25B | 3.44B | 3.66B |
| EBITDA | 508.00M | 509.00M | 455.00M | 801.00M | 931.00M | 1.26B |
| Net Income | 254.00M | 336.00M | 262.00M | 442.00M | 517.00M | 737.00M |
Balance Sheet | ||||||
| Total Assets | 11.79B | 12.66B | 11.72B | 10.87B | 10.31B | 10.07B |
| Cash, Cash Equivalents and Short-Term Investments | 3.19B | 2.95B | 2.69B | 3.02B | 3.04B | 3.56B |
| Total Debt | 490.00M | 20.00M | 22.00M | 24.00M | 27.00M | 28.00M |
| Total Liabilities | 2.11B | 2.70B | 2.17B | 1.84B | 1.69B | 1.75B |
| Stockholders Equity | 9.08B | 9.37B | 8.97B | 8.45B | 8.05B | 7.79B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 366.00M | 25.00M | 636.00M | 180.00M | 507.00M |
| Operating Cash Flow | 0.00 | 595.00M | 241.00M | 736.00M | 284.00M | 648.00M |
| Investing Cash Flow | 0.00 | 43.00M | -217.00M | -758.00M | -291.00M | -145.00M |
| Financing Cash Flow | 0.00 | -283.00M | -479.00M | -201.00M | -236.00M | -420.00M |
Cosmo Bio Co., Ltd. Technical Analysis
Positive
1190.00
Price Trends
1313.44
Negative
1321.64
Negative
1243.98
Positive
Market Momentum
-6.56
Negative
50.50
Neutral
40.15
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:3386, the sentiment is Positive. The current price of 1190 is below the 20-day moving average (MA) of 1277.95, below the 50-day MA of 1313.44, and below the 200-day MA of 1243.98, indicating a neutral trend. The MACD of -6.56 indicates Negative momentum. The RSI at 50.50 is Neutral, neither overbought nor oversold. The STOCH value of 40.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:3386.
Cosmo Bio Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | ¥11.43B | 41.40 | ― | ― | 3.66% | 32.11% | |
70 Outperform | ¥7.18B | 8.02 | ― | 4.57% | 8.02% | 43.89% | |
70 Outperform | ¥9.30B | 21.31 | ― | 2.53% | 3.28% | -30.16% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | ¥9.86B | -10.08 | ― | ― | -62.06% | 7.56% | |
48 Neutral | ¥6.45B | -12.20 | ― | ― | 324.27% | 18.93% | |
45 Neutral | ¥16.07B | -28.17 | ― | ― | -25.02% | -697.06% |
* Healthcare Sector Average
JP:3386
Cosmo Bio Co., Ltd.
1,240.00
133.86
12.10%
JP:4556
Kainos Laboratories, Inc.
2,273.00
1,040.00
84.35%
JP:4570
Immuno-Biological Laboratories Co., Ltd.
1,227.00
746.06
155.13%
JP:4892
Cyfuse Biomedical K.K.
639.00
-424.00
-39.89%
JP:4978
ReproCELL Inc.
169.00
13.00
8.33%
JP:7776
CellSeed Inc.
253.00
-271.00
-51.72%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.